News from us and our partners

Tags

Topics

0 results

News
7 May, 2024
GenSight Biologics raises over €9.2M in share offering
News
6 May, 2024
Mediar advances first-in-class fibrosis portfolio to the clinic with first cohort dosing in Phase 1 trial of MTX-463 and establishes clinical advisory board
News
6 May, 2024
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
News
2 May, 2024
Amolyt Pharma granted FDA Fast Track Designation for eneboparatide for the treatment of hypoparathyroidism
News
2 May, 2024
Biotalys starts field trials for second Biofungicide
News
30 April, 2024
Biotalys appoints Laura J. Meyer to Board of Directors
News
22 April, 2024
Sofinnova’s newest partners discuss their career paths
News
22 April, 2024
Sofinnova Partners appoints two new partners, strengthening team of next generation investors
News
10 April, 2024
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
News
9 April, 2024
Artios Pharma appoints Chris Liu to board
News
8 April, 2024
Sensorion announces a €15 Million financing, extending cash runway until the end of 2025
News
5 April, 2024
Johnson & Johnson to acquire Shockwave Medical
News
3 April, 2024
Moon Surgical expands to gynecological surgery
News
28 March, 2024
Inventiva announces the nomination of Andre Turenne as Director
News
26 March, 2024
Asceneuron joins critical path for Alzheimer’s Disease Consortium
News
21 March, 2024
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease

GenSight Biologics raises over €9.2M in share offering

Mediar advances first-in-class fibrosis portfolio to the clinic with first cohort dosing in Phase 1 trial of MTX-463 and establishes clinical advisory board

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

Amolyt Pharma granted FDA Fast Track Designation for eneboparatide for the treatment of hypoparathyroidism

Biotalys starts field trials for second Biofungicide

Biotalys appoints Laura J. Meyer to Board of Directors

Sofinnova’s newest partners discuss their career paths

Sofinnova Partners appoints two new partners, strengthening team of next generation investors

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Artios Pharma appoints Chris Liu to board

Sensorion announces a €15 Million financing, extending cash runway until the end of 2025

Johnson & Johnson to acquire Shockwave Medical

Moon Surgical expands to gynecological surgery

Inventiva announces the nomination of Andre Turenne as Director

Asceneuron joins critical path for Alzheimer’s Disease Consortium

Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease